Revance Appoints Biotech and Pharmaceutical Executive, Olivia C. Ware, and Fintech and Payments Thought Leader and Entrepreneur, Carey O’Connor Kolaja, to its Board of Directors
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005292/en/
![]() |
![]() |
“As we continue to grow and evolve our company strategy, it is critical that we expand the focus and expertise of our board. Olivia’s extensive background in drug portfolio and program management and Carey’s deep experience in fintech and payments strategy and execution will be invaluable to the board and our organization. We welcome Olivia and Carey to the Revance team and look forward to working with them on our strategic growth initiatives for our aesthetics and therapeutics franchises,” said
The company also announced that long-standing directors
“Phyllis and Bob have been outstanding members of the board and were instrumental in guiding Revance through its evolution for more than a decade,” said
About
“Revance Therapeutics” and the Revance logo are registered trademarks of
Resilient Hyaluronic Acid® and RHA® are trademarks of
BOTOX® is a registered trademark of
Forward-Looking Statements
Any statements in this press release that are not statements of historical fact constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, events, circumstances, or achievements reflected in the forward-looking statements will ever be achieved or occur.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties relate to a variety of economic, competitive, commercial, social, regulatory and operational factors. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this report may be found in our periodic filings with the
“Revance Therapeutics” and the Revance logo are registered trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005292/en/
Investors
jessica.serra@revance.com
or
laurence@gilmartinir.com
Media
sfahy@revance.com
or
General Media:
Goodfuse:
Jenifer Slaw, 347-971-0906
jenifer.slaw@goodfuse.com
or
Trade Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com
Source: